Skip to content

Biohaven BHVN Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Eli Lilly logo
Eli LillyLLY
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
uniQure logo
uniQureQURE
Roivant Sciences logo
Roivant SciencesROIV
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's software and technology licenses, net?
Biohaven (BHVN) reported software and technology licenses, net of $45.71M in Q1 2026.
How has Biohaven's software and technology licenses, net changed year-over-year?
Biohaven's software and technology licenses, net increased by 18.4% year-over-year, from $38.61M to $45.71M.
What is the long-term trend for Biohaven's software and technology licenses, net?
Over 4 years (2021 to 2025), Biohaven's software and technology licenses, net has grown at a 181.0% compound annual growth rate (CAGR), from $760K to $47.36M.